Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis

Molecular Therapy

Volumn 21, Issue 10, 2013, Pages 1919-1929

  Wang, Yuhua ^a   Xu, Zhenghong ^a   Guo, Shutao ^a   Zhang, Lu ^a   Sharma, Arati ^b   Robertson, Gavin P ^b   Huang, Leaf ^a  

^a University of North Carolina   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD47 ANTIGEN; LIPOSOME PROTAMINE HYALURONIC ACID NANOPARTICLE; NANOPARTICLE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER THERAPY; CANCER TISSUE; CELL DESTRUCTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENCAPSULATION; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MACROPHAGE; MELANOMA; METASTASIS INHIBITION; MOUSE; MULTIPLE DRUG DOSE; NANOMEDICINE; NONHUMAN; PHAGOCYTOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; UPREGULATION;

ANIMALIA;

ANIMALS; ANTIGENS, CD47; CELL LINE, TUMOR; CELLS, CULTURED; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; INJECTIONS, INTRAVENOUS; LIPOSOMES; LUNG NEOPLASMS; MACROPHAGES; MELANOMA; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; NANOPARTICLES; PHAGOCYTOSIS; PROGNOSIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 84885023432     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.135     Document Type: Article

References (46)

1. Liang, S, Sharma, A, Peng, HH, Robertson, G and Dong, C (2007). Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res 67: 5814-5820.
2. Cipponi, A, Wieers, G, van Baren, N and Coulie, PG (2011). Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol Immunother 60: 1153-1160.
3. Parmiani, G, Castelli, C, Santinami, M and Rivoltini, L (2007). Melanoma immunology: past, present and future. Curr Opin Oncol 19: 121-127.
4. Umansky, V and Sevko, A (2012). Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol 22: 319-326.
5. Ostrand-Rosenberg, S (2008). Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 18: 11-18.
6. Kusmartsev, S and Gabrilovich, DI (2006). Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 25: 323-331.
7. Rivoltini, L, Canese, P, Huber, V, Iero, M, Pilla, L, Valenti, R et al. (2005). Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? Expert Opin Biol Ther 5: 463-476.
8. Frazier, WA, Gao, AG, Dimitry, J, Chung, J, Brown, EJ, Lindberg, FP et al. (1999). The thrombospondin receptor integrin-associated protein (CD47) functionally couples to heterotrimeric Gi. J Biol Chem 274: 8554-8560.
9. Oldenborg, PA, Zheleznyak, A, Fang, YF, Lagenaur, CF, Gresham, HD and Lindberg, FP (2000). Role of CD47 as a marker of self on red blood cells. Science 288: 2051-2054.
10. Jaiswal, S, Jamieson, CH, Pang, WW, Park, CY, Chao, MP, Majeti, R et al. (2009). CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138: 271-285.
11. Majeti, R, Chao, MP, Alizadeh, AA, Pang, WW, Jaiswal, S, Gibbs, KD Jr et al. (2009). CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138: 286-299.
12. Chan, KS, Espinosa, I, Chao, M, Wong, D, Ailles, L, Diehn, M et al. (2009). Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 106: 14016-14021.
13. Chao, MP, Alizadeh, AA, Tang, C, Myklebust, JH, Varghese, B, Gill, S et al. (2010). Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142: 699-713.
14. Dunn, GP, Old, LJ and Schreiber, RD (2004). The three Es of cancer immunoediting. Annu Rev Immunol 22: 329-360.
15. Kim, D, Wang, J, Willingham, SB, Martin, R, Wernig, G and Weissman, IL (2012). Anti- CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 26: 2538-2545.
16. Edris, B, Weiskopf, K, Volkmer, AK, Volkmer, JP, Willingham, SB, Contreras-Trujillo, H et al. (2012). Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci USA 109: 6656-6661.
17. Chao, MP, Tang, C, Pachynski, RK, Chin, R, Majeti, R and Weissman, IL (2011). Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 118: 4890-4901.
18. Chao, MP, Alizadeh, AA, Tang, C, Jan, M, Weissman-Tsukamoto, R, Zhao, F et al. (2011). Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71: 1374-1384.
19. Willingham, SB, Volkmer, JP, Gentles, AJ, Sahoo, D, Dalerba, P, Mitra, SS et al. (2012). The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109: 6662-6667.
20. Chono, S, Li, SD, Conwell, CC and Huang, L (2008). An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release 131: 64-69.
21. Chen, Y, Zhu, X, Zhang, X, Liu, B and Huang, L (2010). Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 18: 1650-1656.
22. Li, SD and Huang, L (2010). Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release 145: 178-181.
23. Tyner, JW, Uchida, O, Kajiwara, N, Kim, EY, Patel, AC, O'Sullivan, MP et al. (2005). CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nat Med 11: 1180-1187.
24. Seiler, P, Aichele, P, Odermatt, B, Hengartner, H, Zinkernagel, RM and Schwendener, RA (1997). Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection. Eur J Immunol 27: 2626-2633.
25. Zeisberger, SM, Odermatt, B, Marty, C, Zehnder-Fjällman, AH, Ballmer-Hofer, K and Schwendener, RA (2006). Clodronate-liposome-mediated depletion of tumourassociated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 95: 272-281.
26. Yang, Y, Li, J, Liu, F and Huang, L (2012). Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol Ther 20: 609-615.
27. Li, SD, Chono, S and Huang, L (2008). Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther 16: 942-946.
28. Gref, R, Minamitake, Y, Peracchia, MT, Trubetskoy, V, Torchilin, V and Langer, R (1994). Biodegradable long-circulating polymeric nanospheres. Science 263: 1600-1603.
29. Chao, MP, Jaiswal, S, Weissman-Tsukamoto, R, Alizadeh, AA, Gentles, AJ, Volkmer, J et al. (2010). Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2: 63ra94.
30. Subramanian, S, Parthasarathy, R, Sen, S, Boder, ET and Discher, DE (2006). Speciesand cell type-specific interactions between CD47 and human SIRPalpha. Blood 107: 2548-2556.
31. Schwartz, MA, Brown, EJ and Fazeli, B (1993). A 50-kDa integrin-associated protein is required for integrin-regulated calcium entry in endothelial cells. J Biol Chem 268: 19931-19934.
32. Sick, E, Niederhoffer, N, Takeda, K, Landry, Y and Gies, JP (2009). Activation of CD47 receptors causes histamine secretion from mast cells. Cell Mol Life Sci 66: 1271-1282.
33. Pettersen, RD, Hestdal, K, Olafsen, MK, Lie, SO and Lindberg, FP (1999). CD47 signals T cell death. J Immunol 162: 7031-7040.
34. Manna, PP and Frazier, WA (2004). CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A. Cancer Res 64: 1026-1036.
35. Sick, E, Boukhari, A, Deramaudt, T, Rondé, P, Bucher, B, André, P et al. (2011). Activation of CD47 receptors causes proliferation of human astrocytoma but not normal astrocytes via an Akt-dependent pathway. Glia 59: 308-319.
36. Congote, LF and Temmel, N (2004). The C-terminal 26-residue peptide of serpin A1 stimulates proliferation of breast and liver cancer cells: role of protein kinase C and CD47. FEBS Lett 576: 343-347.
37. Lih, CJ, Wei, W and Cohen, SN (2006). Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes Dev 20: 2082-2095.
38. Maxhimer, JB, Soto-Pantoja, DR, Ridnour, LA, Shih, HB, Degraff, WG, Tsokos, M et al. (2009). Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med 1: 3ra7.
39. Maxhimer, JB, Shih, HB, Isenberg, JS, Miller, TW and Roberts, DD (2009). Thrombospondin-1/CD47 blockade following ischemia-reperfusion injury is tissue protective. Plast Reconstr Surg 124: 1880-1889.
40. Sick, E, Jeanne, A, Schneider, C, Dedieu, S, Takeda, K and Martiny, L (2012). CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest. Br J Pharmacol 167: 1415-1430.
41. Isenberg, JS, Maxhimer, JB, Hyodo, F, Pendrak, ML, Ridnour, LA, DeGraff, WG et al. (2008). Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. Am J Pathol 173: 1100-1112.
42. Soto-Pantoja, DR, Miller, TW, Pendrak, ML, DeGraff, WG, Sullivan, C, Ridnour, LA et al. (2012). CD47 deficiency confers cell and tissue radioprotection by activation of autophagy. Autophagy 8: 1628-1642.
43. Matsumura, Y and Maeda, H (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46(12 Pt 1): 6387-6392.
44. Chen, Y, Bathula, SR, Li, J and Huang, L (2010). Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 285: 22639-22650.
45. Banerjee, R, Tyagi, P, Li, S and Huang, L (2004). Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer 112: 693-700.
46. Huh, SJ, Chung, CY, Sharma, A and Robertson, GP (2010). Macrophage inhibitory cytokine-1 regulates melanoma vascular development. Am J Pathol 176: 2948-2957.